Date: 2014-10-14
Type of information: Licensing agreement
Compound: IMX313 pro-immunogenic technology
Company: Imaxio (France) German Cancer Research Center (DKFZ) (Germany)
Therapeutic area: Infectious diseases - Cancer - Oncology
Type agreement: licensing
Action mechanism:
Disease: human papillomavirus (HPV) infections
Details: * On October 14, 2014, Imaxio, a biopharmaceutical company specialized in vaccines, announced that it has signed an option for a license agreement with the German Center for Cancer Research (DKFZ – Deutsches Krebsforschungszentrum), based in Heidelberg. The DKFZ is to make an internal evaluation of Imaxio’s IMX313 pro-immunogenic technology. It will be tested to enhance the efficacy of one of the Center’s candidate vaccines, which is indicated in the prevention of human papillomavirus (HPV) infections. Based on the results of testing, the Center will exercise its license option to continue with development of the candidate vaccine.
Financial terms: The financial terms of the agreement were not disclosed.
Latest news:
